Focused On-demand Library for Nuclear GTPase SLIP-GC

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q68CJ6

UPID:

SLIP_HUMAN

Alternative names:

Speckled-like pattern in the germinal center

Alternative UPACC:

Q68CJ6; Q6ZP73

Background:

Nuclear GTPase SLIP-GC, also known as Speckled-like pattern in the germinal center, plays a pivotal role in the immune system. It is primarily found in germinal center B-cells, where it is believed to inhibit the function of the activation-induced cytidine deaminase AICDA, as suggested by research findings. This inhibition is crucial as it reduces somatic hypermutation in B-cells, potentially enhancing genome stability and preventing aberrant mutations.

Therapeutic significance:

Understanding the role of Nuclear GTPase SLIP-GC could open doors to potential therapeutic strategies. Its ability to modulate somatic hypermutation and influence genome stability in B-cells positions it as a key target for interventions aimed at autoimmune diseases, where B-cell function is often dysregulated.